DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VIVITROL

Summary for Tradename: VIVITROL

Patents:19
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 VIVITROL

Clinical Trials for: VIVITROL

Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
Status: Completed Condition: Bipolar Disorders; Schizophrenia; Schizoaffective Disorders; Alcohol Dependence

Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)
Status: Completed Condition: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Alcohol Dependence

Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial. A Free Treatment for Opiate Abuse.
Status: Completed Condition: Opiate Dependence; Heroin Dependence

Improved Strategies for Outpatient Opioid Detoxification
Status: Recruiting Condition: Opioid Dependence

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
Status: Recruiting Condition: Opiate Dependence

Extended-release Naltrexone for Alcohol Dependence in Primary Care
Status: Completed Condition: Alcohol Dependence

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
Status: Completed Condition: Alcohol Dependence

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
Status: Terminated Condition: Alcoholism; Opiate Dependence

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
Status: Completed Condition: Alcoholism

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease
Status: Completed Condition: Crohn's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897Apr 13, 2006RXYes<disabled><disabled>
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897Apr 13, 2006RXYes5,792,477<disabled>Y<disabled>
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897Apr 13, 2006RXYes5,916,598<disabled>Y<disabled>
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897Apr 13, 2006RXYes6,194,006<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc